Teva Pharma And Polpharma Biologics Announce Global Licensing Agreement Granting Teva Exclusive Rights To Commercialize Both Formulations Of Polpharma Biologics’ Proposed Biosimilar To Ocrevus, Upon Regulatory Approval

Loading news article.

Teva Pharma And Polpharma Biologics Announce Global Licensing Agreement Granting Teva Exclusive Rights To Commercialize Both Formulations Of Polpharma Biologics’ Proposed Biosimilar To Ocrevus, Upon Regulatory Approval | WAPE

Teva Pharma And Polpharma Biologics Announce Global Licensing Agreement Granting Teva Exclusive Rights To Commercialize Both Formulations Of Polpharma Biologics’ Proposed Biosimilar To Ocrevus, Upon Regulatory Approval

Article summary

Related companies

Comments —